Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Robert L. Ferris(University of Pittsburgh), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Jérôme Fayette(Université Claude Bernard Lyon 1), Tamara Rordorf(Institut Gustave Roussy), Naomi Kiyota(Kobe University Hospital), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Lara Carmen Iglesias Docampo(Institut Gustave Roussy), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Vijayvel Jayaprakash(Roswell Park Comprehensive Cancer Center), Robert I. Haddad(Georgetown University), Wei Li(Bristol-Myers Squibb (United States)), Stefan Kasper(Essen University Hospital), Caroline Even(Institut Gustave Roussy), J. Guigay(Centre Antoine Lacassagne)
Cited by 52
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k